THE EFFECT OF ETRASIMOD ON FECAL CALPROTECTIN AND HIGHSENSITIVITY C-REACTIVE PROTEIN: RESULTS FROM THE ELEVATE UC CLINICAL PROGRAM

被引：0
|
作者：
Jairath, Vipul
Rubin, David T.
Verstockt, Bram
Cekin, Ayhan Hilmi
Abreu, Maria T.
Lees, Charlie W.
Fellmann, Marc
Woolcott, John
Crosby, Catherine
Wu, Joseph
Bhattacharjee, Abhishek
Herman, David
Gu, Guibao
Siegmund, Britta
机构：
来源：
GASTROENTEROLOGY | 2024年 / 166卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su1793
引用
收藏
页码：S816 / S816
页数：1
相关论文
共 50 条
  • [21] Combined evaluation of fecal calprotectin and C-reactive protein as a therapeutic target in the management of patients with Crohn's disease
    Cancela Penna, Francisco Guilherme
    Rosa, Rodrigo Macedo
    Pereira, Fernando H.
    Sales Cunha, Pedro Ferrari
    Sousa, Stella Cristina S.
    Ferrari, Teresa Cristina A.
    Cara, Carlos
    Ferrari, Maria de Lourdes A.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2021, 44 (02): : 87 - 95
  • [22] Effect of a program of cardiac rehabilitation on the levels of C-reactive protein
    Nestares Pleguezuelo, M.
    Ramos Mejias, A.
    Sanchez Campos, M.
    de Teresa Galvan, C.
    Sanchez Entrena, E.
    Diaz Castro, J.
    Lopez Frias, M.
    ANNALS OF NUTRITION AND METABOLISM, 2011, 58 : 223 - 223
  • [23] The Effect of Mirikizumab on Fecal Calprotectin and C-Reactive Protein in Phase 3 Studies of Patients With Moderately-to-Severely Active Ulcerative Colitis
    Siegmund, Britta
    Sands, Bruce E.
    Samaan, Karen
    Li, Xingyuan
    Morris, Nathan
    Gibble, Theresa Hunter
    Redondo, Isabel
    Lissoos, Trevor
    D'Haens, Geert
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S543 - S544
  • [24] Evaluating the Efficacy of Fecal Immunochemical Test, Fecal Calprotectin, and Serum C-Reactive Protein in Diagnosing Patients With Chronic Lower Gastrointestinal Symptoms
    Limsrivilai, Julajak
    Yodmalai, Chatrawee
    Chaemsupaphan, Thanaboon
    Sattayalertyanyong, Onuma
    Subdee, Nichcha
    Permpim, Parinya
    Phaophu, Phutthaphorn
    Kaosombatwattana, Uayporn
    Pausawasdi, Nonthalee
    Riansuwan, Woramin
    Charatcharoenwitthaya, Phunchai
    Pongprasobchai, Supot
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2024, 15 (08)
  • [25] The Utility of C-Reactive Protein, Erythrocyte Sedimentation Rate, Fecal Calprotectin and Fecal Lactoferrin to Exclude Inflammatory Bowel Disease in Adults With IBS
    Dai, Cong
    Jiang, Min
    Sun, Ming-Jun
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2015, 110 (08): : 1242 - 1243
  • [26] Health-Related Quality of Life From the Inflammatory Bowel Disease Questionnaire in Patients with Ulcerative Colitis Stratified by Prior & Concomitant Therapies: Results From the Etrasimod ELEVATE UC Clinical Program
    Armuzzi, Alessandro
    Rubin, David T.
    Schreiber, Stefan
    Panes, Julian
    Fellmann, Marc
    Bartolome, Lauren
    Goetsch, Martina
    Bhattacharjee, Abhishek
    Wu, Joseph
    Chaparro, MariIa
    Dubinsky, Marla C.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S683 - S684
  • [27] Clinical symptoms, C-reactive protein, calprotectin, MRI or endoscopy? Stragegies for therapy monitoring of IBD
    Prager, M.
    Buening, C.
    COLOPROCTOLOGY, 2014, 36 (04) : 250 - 258
  • [28] Clinical symptoms, C-reactive protein, calprotectin, MRI or endoscopy? Stragegies for therapy monitoring of IBD
    Prager, M.
    Buening, C.
    GASTROENTEROLOGE, 2013, 8 (03): : 187 - 196
  • [29] Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs' treatment effect on C-reactive protein
    Benhamou, Mathilde
    Gossec, Laure
    Dougados, Maxime
    RHEUMATOLOGY, 2010, 49 (03) : 536 - 541
  • [30] Fecal calprotectin and serum C-reactive protein predict outcome of infliximab induction therapy in inflammatory bowel disease.
    Hellstrom, P. M.
    Diaz, H.
    Lonnkvist, M.
    Befrits, R.
    JOURNAL OF CROHNS & COLITIS, 2015, 9 : S287 - S288
12345